GlassScriptPhysician profile
Meredith L Buckner
NPI 1811356801
$1,531.06
in general payments reported to CMS, 2019-2025
24 companies · $40.63 in 2025
The $40.63 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $481 · 2022: $435 · 2023: $340 · 2024: $234 · 2025: $40.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $252.29 | 2021-2024 | Enhertu |
| Amgen INC. | $197.90 | 2021-2023 | Lumakras |
| Celgene Corporation | $161.02 | 2021-2024 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $155.07 | 2021-2024 | Opdivo |
| Genzyme Corporation | $131.78 | 2021-2023 | |
| Janssen Biotech, INC. | $81.39 | 2021-2024 | Tecvayli |
| Incyte Corporation | $59.47 | 2022-2023 | Jakafi |
| Seagen INC. | $53.35 | 2022-2023 | Tukysa |
| Kite Pharma, INC. | $48.45 | 2024-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $45.47 | 2024-2025 | Qinlock, Romvimza |
| Pfizer INC. | $44.22 | 2021-2024 | |
| Daiichi Sankyo INC. | $40.77 | 2022-2023 | Injectafer |
| Glaxosmithkline, LLC. | $38.96 | 2023 | Jemperli |
| Puma Biotechnology, INC. | $32.03 | 2021 | |
| Genentech USA, INC. | $30.24 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.52 | 2022 | |
| Acrotech Biopharma INC. | $20.57 | 2023 | Beleodaq |
| Abbvie INC. | $19.59 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.87 | 2023 | |
| Array Biopharma INC | $17.42 | 2023 | Mektovi, Xalkori, Braftovi |
| Gilead Sciences, INC. | $14.79 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $11.87 | 2021 | |
| Epizyme, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.